Ipsen moves ahead in cancer

Ipsen SA reported its best annual results so far in 2017 with consolidated revenue rising by 20.4% to €2.0 billion and operating profit gaining 30.4% to €397.2 million. The French company’s market value rose by 45.5% for the year to €8.3 billion, reflecting the strong performance.

Full text available to subscribers only. Click here for information on subscribing to MedNous.